Long-term survival is linked to serum LDH and partly to tumour LDH-5 in NSCLC
By: Danner BC, Didilis VN, Wiemeyer S, Stojanovic T, Kitz J, Emmert A, Füzesi L, Schöndube FA.

Department of Thoracic and Cardiovascular Surgery, University of Göttingen, Göttingen, Germany. bdanner@med.uni-goettingen.de
Anticancer Res. 2010 Apr; 30(4):1347-51.

Abstract

Background

Lactate formation is up-regulated in tumorous cells by lactate dehydrogenase (LDH). High serum LDH level is linked to many malignancies with poorer survival, but tumour LDH-5 has not been well investigated in non-small cell lung cancer (NSCLC).

Patients and Methods

In 89 patients operated on for NSCLC stage I-III, the serum LDH level was assayed and immunohistochemistry for tumour LDH-5 was performed. Impact on long-term survival and correlation was analysed.

Results

High serum LDH was associated with poorer survival (p<0.001). No correlation was revealed between serum LDH and the tumour LDH-5. Only in tumours greater than 3 cm were high tumour LDH-5 values associated with higher serum LDH values (p=0.04) and in this subgroup, high tumor LDH-5 was associated with poorer long-term survival (p=0.024).

Conclusion

High serum LDH has a negative impact on long-term survival in NSCLC, whereas for tumour LDH-5, this was seen only in a subgroup of patients with larger tumours.

PMID: 20530451 [PubMed - indexed for MEDLINE] Source: National Library of Medicine.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements